Intended Use

“MagQu” Phosphorylated Tau protein [pT217] IMR Reagent  is used to quantitatively measure phosphorylated Tau protein(p-Tau217) in human fluid specimen, such as plasma, serum or CSF.

Use “MagQu” Phosphorylated Tau protein [pT217] IMR Reagent only with the XacPro-S System (MagQu Co., Ltd.). 

Introduction

Tau protein is a microtubule-associated protein and is abundant in nervous system. Tau protein can maintain the structure of neuron cells and support the transport of substance. When tau proteins phosphorylated, It will result in the self-assembly of tangles in brain and increased some neurodegenerative diseasesincluding Alzheimer’s disease (AD)、Pick's disease、Parkinson's disease (PD)、Progressive supranuclear palsy(PSP) and Corticobasal degeneration (CBD). Plasma phosphorylated Tau protein 217 (p-Tau217) increased in the preclinical and early clinical stages of Alzheimer’s disease.^1,2

Principles of Test

“MagQu” Phosphorylated Tau protein [pT217] IMR Reagent is designed for rapid quantifying phosphorylated Tau protein(p-Tau217) by Immuno Magnetic Reduction (IMR). We conjugated the antibody on the surface of around 50 nm-in-diameter Fe₃O₄ magnetic particles. When the antibodies on the surface bind with phosphorylated Tau protein (p-Tau217), the magnetic particles form clusters. Therefore, the ac susceptibility (Xac) of magnetic particles would be reduced in the adding ac magnetic field. By measuring the reduction of Xac, we can quantify phosphorylated Tau protein(p-Tau181) in the sample easily, rapidly, and accurately.³

References

1.Suárez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodríguez J, Milà-Alomà M, Gispert JD, Salvadó G, Minguillon C, Fauria K, Shekari M, Grau-Rivera O, Arenaza- Urquijo EM, Sala-Vila A, Sánchez-Benavides G, González-de-Echávarri JM, Kollmorgen G, Stoops E, Vanmechelen E, Zetterberg H, Blennow K, Molinuevo JL; ALFA Study. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in Aβ pathology are detected. EMBO Mol Med. 2020 Dec 7;12(12):e12921.

2.Yang SY, Chiu MJ, Chen TF, Horng HE. Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. Neurol Ther. 2017 Jul;6(Suppl 1):37-56.

3.Yang CC, Yang SY, Ho CS, Chang JF, Liu BH, Huang KW. Development of antibody functionalized magnetic nanoparticles for the immunoassay of carcinoembryonic antigen: a feasibility study for clinical use. J Nanobiotechnology. 2014 Nov 26;12:44.